The deal will establish ResMed as a leader in COPD patient management, across all stages of the disease; Propeller Health to continue operating as a standalone business.
Propeller's FDA-cleared digital solution will be provided to Express Scripts members using inhaler sensors and a mobile app to manage asthma or COPD.
Called Air by Propeller, it provides local asthma conditions to anyone in the US who would like to share this insight with their audiences.
The two companies will undertake commercial activities using the Propeller clip-on sensor and software platform for use with GSK's ELLIPTA Inhaler.
The new custom sensors will allow for passively recording compliance data, better informing patients and their physicians of adherence and other factors.
The initial focus of the collaboration will be the development of an add-on sensor for Vectura's lever-operated multi-dose inhaler (LOMI).
The study demonstrated effectiveness of the Propeller Health Asthma Management Platform to better manage chronic respiratory disease.
Patients will have the opportunity to enroll in a new program to determine how Propeller's hi-tech tool can impact adherence rates and patient engagement.
The sensor-laden device with a novel electronic dose counter is currently available for licensing and is expected to enter clinical studies later this year.
GSK will use the sensor in the studies to automatically collect and record data on the inhaler's usage, and wirelessly transmit the data collected.